Keywords: elan/biogen, evaluation, tysabri, safety, data, finds, new

Elan/Biogen evaluation of Tysabri safety data finds no new evidence of PML

Article | 15 August 2005

Print This

Following the suspension of the multiple sclerosis drug Tysabri (natalizumab) in February due to the emergence of three cases of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in